Sodium alginate + Sodium hydrogen carbonate + Calcium carbonate
This medicine should always be used exactly as described in this patient leaflet or as directed by a doctor or pharmacist.
Gaviscon duo tab mint flavor is a combination of alginate and two acid-neutralizing agents (calcium carbonate and sodium hydrogen carbonate) that work in two ways:
This medicine is used to treat symptoms of acid reflux, such as heartburn, acid regurgitation, and indigestion, for example after meals or during pregnancy.
Like other acid-neutralizing medicines, taking this medicine may mask the symptoms of other, more serious diseases.
The patient should not take this medicine within 2 hours of taking other oral medicines, as it may interfere with their action. This is especially important if the patient is taking antihistamines, antibiotics (tetracyclines and quinolones, such as norfloxacin), iron preparations, thyroid hormones, antifungal medicines (such as ketoconazole), digoxin, and beta-adrenolytics (used in heart diseases), neuroleptics (used in mental illnesses), thyroxine, chloroquine (used in malaria), bisphosphonates (used in osteoporosis), and estramustine (used in prostate cancer). The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The patient can take this medicine if they are pregnant, breastfeeding, or planning to have a child. As with all medicines, the duration of treatment should be as short as possible.
This medicine contains 5.86 mg of aspartame (E951) in each chewable tablet. Aspartame is a source of phenylalanine. It may be harmful if the patient has phenylketonuria, a rare genetic disorder in which phenylalanine accumulates, as the body cannot remove it properly. The chewable tablets contain azorubine (E122), which may cause an allergic reaction. The medicine contains 223.7 mg (9.728 mmol) of sodium in a dose of four chewable tablets. The maximum recommended daily dose of this medicine contains 895 mg of sodium (found in salt). This corresponds to 44.75% of the recommended maximum daily sodium intake for an adult. If the patient takes this medicine daily for a long time, they should talk to their pharmacist or doctor, especially if they have been advised to follow a low-sodium diet. The medicine contains 300 mg (7.5 mmol) of calcium in a dose of four chewable tablets. Before taking this medicine, the patient should talk to their doctor if they have kidney stones or high calcium levels in the blood. If the patient has previously been diagnosed with intolerance to some sugars, they should consult their doctor before taking this medicine.
This medicine should always be used exactly as described in this patient leaflet or as directed by a doctor or pharmacist. In case of doubt, the patient should consult their doctor or pharmacist. Oral administration. Chew thoroughly before swallowing. Adults and adolescents over 12 years:If symptoms occur, take 2 to 4 chewable tablets after meals and before bedtime, up to 4 times a day. Children under 12 years:Not recommended for children under 12 years.
It is unlikely that taking too much of this medicine will harm the patient. However, they may experience bloating and abdominal discomfort. If the symptoms do not go away, the patient should consult their doctor. Missing a dose of this medicine:The patient should not take a double dose to make up for a missed dose. They should continue taking the medicine as before.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If the patient experiences side effects, they should stop taking the medicine and consult their doctor immediately. Very rarely (may affect up to 1 in 10,000 people), an allergic reaction to the ingredients of the medicine may occur. Symptoms may include abdominal pain, diarrhea, nausea, vomiting, rash, itching, dizziness, facial swelling, lip swelling, tongue swelling, or throat swelling, and difficulty breathing. Taking large amounts of calcium carbonate, an ingredient of this medicine, may cause elevated blood pH (alkalosis), high calcium levels in the blood (hypercalcemia), increased stomach acid production, and constipation. These usually occur after taking higher than recommended doses.
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children. Do not use this medicine after the expiry date stated on the carton and blister after "EXP". The expiry date refers to the last day of the month stated. Do not store above 30°C. Store in the original package to protect from moisture. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substances in each chewable tablet are 250 mg of sodium alginate, 106.5 mg of sodium hydrogen carbonate, and 187.5 mg of calcium carbonate. The other ingredients are: macrogol 20, mannitol type 100, copovidone, peppermint flavor (containing sucrose, maltodextrin, and gum arabic), acesulfame potassium, aspartame (E951), azorubine, aluminum lake (E122), magnesium stearate, xylitol.
Flat, round, two-layer chewable tablets with a mint flavor and smell. One layer of the chewable tablet is pink and has a slightly speckled appearance with GDA markings on the surface, and the other layer is white with sword and circle markings. This medicine is available in packages containing 12, 16, 24, 32, 48, 60 chewable tablets. Not all pack sizes may be marketed.
Reckitt Benckiser (Poland) S.A., ul. Okunin 1, 05-100 Nowy Dwór Mazowiecki, tel. 0 801 88 88 07
RB NL Brands B.V., Schiphol Boulevard 207, 1118 BH Schiphol, Netherlands
Austria | GAVISCON DUAL Mintgeschmack 250 mg/106,5 mg/187,5 mg Kautabletten |
Bulgaria | Gaviscon Double Action Peppermint chewable tablets |
Denmark | Galieve Extra Peppermint |
Estonia | Gaviscon |
Finland | Galieve Dual Peppermint |
France | Gaviscon Antiacide – Antireflux MENTHE SANS SUCRE, comprimé à croquer édulcoré à l'aspartam et à l'acésulfame potassique |
Netherlands | Gaviscon Duo muntsmaak 250 mg /106,5 mg/187,5 mg, kauwtabletten |
Iceland | Galieve Forte piparmyntu tuggutöflur |
Lithuania | Gaviscon 250 mg/106,5 mg/187,5 mg kramtomosios tabletės |
Latvia | Gaviscon 250 mg/106,5 mg/187,5 mg košļājamās tabletes |
Norway | Galieve Forte |
Poland | Gaviscon duo tab o smaku mięty |
Portugal | Gaviscon Duefet |
Romania | Gaviscon Forte Mentol comprimate masticabile |
Hungary | GAVISCON FORTE borsmenta ízű rágótabletta |
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.